Impact of dorzolamide, benzalkonium-preserved dorzolamide and benzalkonium-preserved brinzolamide on selected biomarkers of oxidative stress in the tear film.
Benzalkonium chloride
Brinzolamide
Carbonic anhydrase inhibitor
Dorzolamide
Glaucoma
Ocular surface
Oxidative stress
Journal
BMC ophthalmology
ISSN: 1471-2415
Titre abrégé: BMC Ophthalmol
Pays: England
ID NLM: 100967802
Informations de publication
Date de publication:
01 Sep 2021
01 Sep 2021
Historique:
received:
08
02
2021
accepted:
14
08
2021
entrez:
2
9
2021
pubmed:
3
9
2021
medline:
4
9
2021
Statut:
epublish
Résumé
Long-term use of topical, especially benzalkonium chloride (BAC)-preserved, antiglaucoma medications can cause a negative impact on the ocular surface. The aim of the study was to assess the effect of topical carbonic anhydrase inhibitors (CAIs) on selected oxidative stress biomarkers in the tear film. The patients were divided into four sex-matched groups: group C (n = 25) - control group - subjects who did not use topical antiglaucoma medications, group DL (n = 14) - patients using preservative-free dorzolamide, group DL + BAC (n = 16) - patients using topical BAC-preserved dorzolamide, group BL + BAC (n = 17) - patients using BAC-preserved brinzolamide. Subjects in all the study groups have been using the eye drops two times daily for 6-12 months. The oxidative stress biomarkers in the tear film samples were measured: total protein (TP) concentration, advanced oxidation protein products (AOPP) content, total sulfhydryl (-SH) groups content, the activity of superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx), as well as Total Oxidant Status (TOS), Total Antioxidant Response (TAR), and Oxidative Stress Index (OSI). The advanced oxidation protein products content, Total Oxidant Status as well as superoxide dismutase and catalase activities in the group DL + BAC and BL + BAC were higher in comparison with the group C. The total sulfhydryl groups content was lower in the group DL + BAC and BL + BAC when compared to group C. Oxidative Stress Index was higher in the groups DL + BAC and BL + BAC in comparison with the groups DL and C. Use of topical benzalkonium chloride-preserved carbonic anhydrase inhibitors increases oxidative stress in the tear film.
Sections du résumé
BACKGROUND
BACKGROUND
Long-term use of topical, especially benzalkonium chloride (BAC)-preserved, antiglaucoma medications can cause a negative impact on the ocular surface. The aim of the study was to assess the effect of topical carbonic anhydrase inhibitors (CAIs) on selected oxidative stress biomarkers in the tear film.
METHODS
METHODS
The patients were divided into four sex-matched groups: group C (n = 25) - control group - subjects who did not use topical antiglaucoma medications, group DL (n = 14) - patients using preservative-free dorzolamide, group DL + BAC (n = 16) - patients using topical BAC-preserved dorzolamide, group BL + BAC (n = 17) - patients using BAC-preserved brinzolamide. Subjects in all the study groups have been using the eye drops two times daily for 6-12 months. The oxidative stress biomarkers in the tear film samples were measured: total protein (TP) concentration, advanced oxidation protein products (AOPP) content, total sulfhydryl (-SH) groups content, the activity of superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx), as well as Total Oxidant Status (TOS), Total Antioxidant Response (TAR), and Oxidative Stress Index (OSI).
RESULTS
RESULTS
The advanced oxidation protein products content, Total Oxidant Status as well as superoxide dismutase and catalase activities in the group DL + BAC and BL + BAC were higher in comparison with the group C. The total sulfhydryl groups content was lower in the group DL + BAC and BL + BAC when compared to group C. Oxidative Stress Index was higher in the groups DL + BAC and BL + BAC in comparison with the groups DL and C.
CONCLUSIONS
CONCLUSIONS
Use of topical benzalkonium chloride-preserved carbonic anhydrase inhibitors increases oxidative stress in the tear film.
Identifiants
pubmed: 34470600
doi: 10.1186/s12886-021-02079-y
pii: 10.1186/s12886-021-02079-y
pmc: PMC8411550
doi:
Substances chimiques
Benzalkonium Compounds
0
Biomarkers
0
Carbonic Anhydrase Inhibitors
0
Ophthalmic Solutions
0
Sulfonamides
0
Thiazines
0
Thiophenes
0
brinzolamide
9451Z89515
dorzolamide
9JDX055TW1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
319Subventions
Organisme : Medical University of Silesia in Katowice
ID : PCN-2-036/N/0/O
Informations de copyright
© 2021. The Author(s).
Références
Cutan Ocul Toxicol. 2020 Sep;39(3):260-268
pubmed: 32594785
Curr Eye Res. 2008 Apr;33(4):303-12
pubmed: 18398704
PLoS One. 2015 May 29;10(5):e0126561
pubmed: 26024535
Clin Biochem. 2004 Feb;37(2):112-9
pubmed: 14725941
Clin Ophthalmol. 2016 Mar 15;10:445-54
pubmed: 27041987
Invest Ophthalmol Vis Sci. 2014 Sep 09;55(10):6499-504
pubmed: 25205861
Trans Am Ophthalmol Soc. 2012 Dec;110:40-63
pubmed: 23818734
Clin Biochem. 2005 Dec;38(12):1103-11
pubmed: 16214125
J Glaucoma. 2008 Aug;17(5):350-5
pubmed: 18703943
Exp Eye Res. 2007 Mar;84(3):389-99
pubmed: 17196589
Ann Anat. 2019 Mar;222:129-138
pubmed: 30580056
Clin Exp Ophthalmol. 2020 Sep;48(7):973-982
pubmed: 32564453
Clin Ophthalmol. 2012;6:2059-62
pubmed: 23271886
Clin Ophthalmol. 2020 Jan 14;14:103-111
pubmed: 32021074
Expert Opin Drug Metab Toxicol. 2016 Nov;12(11):1279-1289
pubmed: 27398637
Arch Biochem Biophys. 1959 May;82(1):70-7
pubmed: 13650640
Ocul Immunol Inflamm. 2010 Aug;18(4):244-53
pubmed: 20482396
Toxicol In Vitro. 2017 Jun;41:21-29
pubmed: 28214551
Biochem J. 2016 Jul 15;473(14):2023-32
pubmed: 27407171
Invest Ophthalmol Vis Sci. 2012 Apr 06;53(4):1792-802
pubmed: 22410563
Mol Vis. 2011;17:3364-70
pubmed: 22219631
PLoS One. 2011;6(10):e26103
pubmed: 22022526
Cornea. 2006 May;25(4):432-7
pubmed: 16670481
J Ocul Pharmacol Ther. 2014 Aug;30(6):476-81
pubmed: 24787056
Medicina (Kaunas). 2019 Jul 11;55(7):
pubmed: 31336766
Ocul Surf. 2009 Oct;7(4):176-85
pubmed: 19948101
Graefes Arch Clin Exp Ophthalmol. 2007 Apr;245(4):534-46
pubmed: 16900358
Free Radic Res. 2016;50(2):246-71
pubmed: 26695718
Graefes Arch Clin Exp Ophthalmol. 2010 Dec;248(12):1757-64
pubmed: 20437244
Kidney Int. 1996 May;49(5):1304-13
pubmed: 8731095
Ocul Surf. 2017 Jul;15(3):511-538
pubmed: 28736341
Invest Ophthalmol Vis Sci. 2012 Dec 13;53(13):8172-80
pubmed: 23150620
Pharmacol Res. 2012 Jul;66(1):19-32
pubmed: 22433276
Mol Aspects Med. 2009 Feb-Apr;30(1-2):1-12
pubmed: 18796312
Invest Ophthalmol Vis Sci. 2004 May;45(5):1360-8
pubmed: 15111589
Eur J Ophthalmol. 2007 May-Jun;17(3):341-9
pubmed: 17534814
Br J Ophthalmol. 2018 Nov;102(11):1497-1503
pubmed: 29973365
Cornea. 2012 Nov;31 Suppl 1:S63-7
pubmed: 23038038
Eur J Ophthalmol. 2008 May-Jun;18(3):400-7
pubmed: 18465723
Prog Retin Eye Res. 2010 Jul;29(4):312-34
pubmed: 20302969
Clin Chim Acta. 2006 Jul 15;369(1):17-28
pubmed: 16516878
Acta Ophthalmol. 2018 Jun;96(4):e412-e420
pubmed: 28834388
Clin Ophthalmol. 2019 Aug 01;13:1409-1425
pubmed: 31447543
Rom J Ophthalmol. 2019 Jul-Sep;63(3):249-256
pubmed: 31687627
Br J Ophthalmol. 2002 Apr;86(4):418-23
pubmed: 11914211
Mol Vis. 2017 Jul 28;23:529-537
pubmed: 28761326
Clin Interv Aging. 2014 Apr 11;9:637-52
pubmed: 24748782